Intestinal dysfunction in cirrhosis patients is linked to death by bacterial infections. Currently, there is no effective therapy for this complication. This study aims to evaluate butyrate, a novel postbiotic, on the intestinal inflammatory response, tight junction proteins, and the microbiota in the cholestasis model. Butyrate is effective in regulating the inflammatory response, tight junction proteins, and limits bacterial diversity loss. CLICK TO REVIEW